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ttp://dx.doi.org/10.1016/j.ajpath.2014.09.012Microphthalmia-associated transcription factor (MITF) acts via pigment epithelium-derived factor
(PEDF), an antiangiogenic protein, to regulate retinal pigment epithelium migration. PEDF expression
and/or regulation during melanoma development have not been investigated previously. Using immu-
nohistochemistry, we determined expression of PEDF in common and dysplastic melanocytic nevi, mel-
anoma in situ, invasive melanoma, and metastatic melanoma (n Z 102). PEDF expression was
consistently decreased in invasive and metastatic melanoma, compared with nevi and melanoma in situ
(P < 0.0001). PEDF was lost in thicker melanomas (PZ 0.003), and correlated with depth of invasion
(PZ 0.003) and distant metastasis (PZ 0.0331), but only marginally with mitotic index, AJCC stage,
nodal metastasis, or blood vascular density (0.05< P< 0.10). Quantitative real-time PCR and microarray
analyses conﬁrmed PEDF down-regulation at the mRNA level in several melanoma lines, compared with
melanocytes. MITF positively correlated with PEDF expression in invasive melanomas (P Z 0.0003).
Searching for PEDF regulatory mechanisms revealed two occupied conserved E-boxes (DNA recognition
elements) in the ﬁrst intron of the human and mouse PEDF promoter regions, conﬁrmed by binding as-
says. Dominant-negative and siRNA approaches in vivo demonstrated direct transcriptional inﬂuence of
MITF on PEDF, establishing the PEDF gene (SERPINF1) as a MITF target in melanocytes and melanoma
cells. These ﬁndings suggest that loss of PEDF expression promotes early invasive melanoma growth.
(Am J Pathol 2015, 185: 252e265; http://dx.doi.org/10.1016/j.ajpath.2014.09.012)Supported by NIH grants 1-P01-CA163222 and R01-AR043369-17
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(D.E.F.), and the American Cancer Society New England Division (R.J.L.).
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R.J.L., NYU Langone Medical Center, New York, NYThe incidence and mortality of melanoma have continually
increased for decades in the United States, and the difﬁ-
culties of clinical management remain a signiﬁcant chal-
lenge.1 Genetically, melanoma is a highly heterogeneous
disease exempliﬁed by numerous recurrent chromosomal
rearrangements, gene ampliﬁcations, point mutations, and a
highly complex miRNA transcriptome,2 as well as by in-
teractions with the environment.3,4 Characterization of these
genetic events has deﬁned several key signaling pathways
involved in melanoma development, leading to rational
targeted therapies5,6 and immunotherapy breakthroughs.7
Cutaneous melanoma has a propensity for early micro-
scopic dissemination to sentinel lymph nodes. Severalstigative Pathology.
.investigators have independently demonstrated that nodal
metastasis is associated with lymphangiogenesis (ie, for-
mation of new lymphatic vessels) in human melanoma8e12
PEDF Down-Regulation in Melanomaand in mouse xenograft models.13,14 Importantly, lymphatic
invasion, deﬁned as the presence of tumor cells within
intraluminal lymphatic spaces, may represent an early step
whereby melanoma cells gain entry into lymphatic vessels
by interacting with newly formed vessels in the dermis.15
Indeed, lymphatic invasion was strongly associated with
melanoma metastasis to sentinel lymph nodes in a cohort of
94 patients16 and with poorer survival in a cohort of 251
patients.17 By contrast, the role of tumor angiogenesis (ie,
formation of new blood vessels) in melanoma progression
and as a prognostic marker has been shown to be less sig-
niﬁcant. A recent systematic and meta-analysis of angio-
genesis, lymphangiogenesis, and lymphatic invasion in
melanoma, based on 26 published studies in 1695 patients,
demonstrated that lymphangiogenesis and lymphatic inva-
sion (but not angiogenesis) had prognostic values in these
patients.18
Although lymphatic dissemination may reﬂect the meta-
static propensity of melanoma, tumor angiogenesis has a
major inﬂuence on melanoma growth, but the balance of
secreted factors promoting or inhibiting angiogenesis in
melanoma is yet to be deﬁned.19 Pigment epithelium-
derived factor (PEDF), a serine protease inhibitor (serpin)
encoded by SERPINF1 (alias PEDF), is a potent inhibitor of
angiogenesis,20 one that can antagonize vascular endothelial
growth factor (VEGF).21 Originally, the PEDF protein,
isolated from cultured retinal pigment epithelial (RPE) cells,
was shown to have neurotrophic activity on retinoblastoma
tumor cells.22 Given that PEDF is a ligand for four diverse
receptors, receptor binding of dysregulated PEDF can cause
a wide range of pathological conditions, including eye
neovascularization, lipid metabolism, cardiovascular dis-
ease, and cancer (reviewed by Craword et al23). PEDF has
been shown to have antitumorigenic and antimetastatic ac-
tivities in a number of human malignancies, including
melanoma, and in mouse xenograft models (reviewed by
Becerra and Notario24). For example, overexpression of
PEDF decreases angiogenesis and can inhibit melanoma
growth25 and metastasis26 in mouse xenograft models.
Moreover, it has been shown by immunohistochemistry
(IHC) that PEDF is expressed in human melanocytic tumors
(melanocytic nevi and melanoma), but not in non-
melanocytic tumors (eg, carcinomas of various organs).27
No previous study has investigated the expression of
PEDF during the various stages of melanoma development
or the mechanism of its cell-speciﬁc regulated expression.
Melanocytes express multiple lineage markers and
microphthalmia-associated transcription factor (MITF),
which encodes a Myc-related transcription factor essential
for melanocyte development.28,29 In humans, mutations of
MITF produce Waardenburg syndrome type 2A, a condition
associated with melanocyte deﬁciencies in the hair follicle,
skin, and inner ear.29 MITF is part of the MiT family of
transcription factors that includes TFEB, TFEC, and TFE3,
which are able to homodimerize and heterodimerize with
each other; MITF appears to be the dominant familyThe American Journal of Pathology - ajp.amjpathol.orgmember within melanocytes. MITF regulates target gene
expression through the binding of the canonical E-box
promoter sequence CACGTG or the nonpalindromic
sequence CACATG.28,29 Mutational analyses suggest that
MITF mediates several discrete functions in the melanocyte
lineage, including regulation of differentiation as well as
proliferation and survival.30 Among the transcriptional tar-
gets believed to be regulated by MITF are survival factors
(BCL2, BCL2A1), pigmentation enzyme-related genes, the
metabolic regulator PGC1a, DNA repair machinery, and
factors involved in cellular migration or invasion.
Despite the established transcription factoretarget gene
relationship between MITF and PEDF in RPE cells,31 this
relationship has not previously been explored in melano-
cytes or in the various stages of melanoma development. In
the present study, we identiﬁed PEDF as a direct tran-
scriptional target of MITF in melanocytes and in melanoma
cell lines using genomic and biochemical analyses. Our IHC
analysis of a series of human clinical specimens (n Z 102)
spanning the spectrum of benign melanocytic nevi to met-
astatic melanoma identiﬁed PEDF down-regulation during
melanoma progression and metastasis. PEDF expression
correlated inversely with tumor thickness, a known prog-
nostic indicator of survival.
Materials and Methods
Immunoﬂuorescence and IHC
Cultured primary human melanocytes were double-stained
using a mouse monoclonal antibody against PEDF (dilution
1:100; Chemicon; EMD Millipore, Billerica, MA), followed
by incubation with the respective secondary antibodies
labeled with either Texas Red or ﬂuorescein isothiocyanate
(both at dilution 1:50; Jackson ImmunoResearch, West
Grove, PA), as described previously.32 Cell nuclei were
counterstained with Hoechst bisbenzimide (Sigma-Aldrich,
St. Louis, MO) at 20 mg/mL.
We used 102 formalin-ﬁxed, parafﬁn-embedded specimens
from 102 patients having undergone a biopsy and/or excision
of a melanocytic lesion from the Pathology Departments of
Brigham and Women’s Hospital, Massachusetts General
Hospital, or Stanford University Medical Center. These
specimens comprised common melanocytic nevi (CN) (n Z
13), dysplastic melanocytic nevi (n Z 3), melanoma in situ
(MIS) (n Z 13), primary cutaneous melanomas (PCM, n Z
61), and metastatic melanomas to skin or lymph node (MM)
(n Z 12). The diagnoses were conﬁrmed by two board-
certiﬁed pathologists or dermatopathologists. The institu-
tional review boards of the three hospitals approved this pro-
tocol. Formalin-ﬁxed, parafﬁn-embedded sections (4 mm
thick) were cut and mounted on Superfrost Plus slides
(Thermo Fisher Scientiﬁc, Waltham, MA). The sections were
then deparafﬁnized and hydrated by passing through xylene
and a graded series of ethanol. Antigen retrieval was per-
formed for 30 minutes at 37C by trypsinization, and then253
Dadras et alendogenous peroxidase activity was inhibited in 0.3%
hydrogen peroxide for 10 minutes. After blocking for 10 mi-
nutes in 0.75% normal horse serum, the sections were incu-
bated with mouse monoclonal PEDF antibody (dilution 1:100;
Chemicon; EMDMillipore) for 1 hour at room temperature or
MITF antibody as previous described.33 We developed the
immunohistochemical stain using an ABC Elite kit (Dako,
Carpinteria, CA) at 1:200 dilution for 1.5 hours, according to
the manufacturer’s instructions. Hematoxylin was used for
counterstaining. During antibody optimization, a negative
control (no primary antibody) was included; this was
completely negative (data not shown). The ﬁnal slides were
examined using a Nikon E-600 microscope (Nikon, Melville,
NY); digital images were captured using a SPOT Imaging
Solutions digital camera (Diagnostic Instruments, Sterling
Heights, MI).
Immunoscoring and Statistical Analysis
A semi-quantitative, four-point ordinal immunoreactivity
score was established. A PEDF signal detected in <10% of
tumor cells was scored as negative reactivity (0); positive
reactivity was deﬁned as a PEDF signal detected in 11% of
tumor cells and was scored as 1 for weakly positive staining in
epidermal or follicular keratinocytes, 2 for moderately positive
staining in epidermal or follicular keratinocytes, and 3
(strongly positive) for diffuse and homogeneous staining in the
cytoplasm and nucleolus. Immunostaining of tumor cells was
scored in comparison with adjacent keratinocytes (internal
positive control). Melanophages (specialized macrophages
containing dark, brown coarse melanin pigment) were not
scored. Two investigators (S.S.D. and G.R.) scored the stained
slides independently. Individual and repeated scores were
averaged, and ﬁnal PEDF values were categorized into a three-
level grouping of negative, low (>0 and1.5), or high (1.6)
for analyses that included all 102 lesions (Table 1).
Boxplots were generated and KruskaleWallis testing was
performed for overall comparison among all diagnostic
groups. Bonferroni procedure, based on the ranks of the
observations, was used for multiple pairwise comparisons
(family level of signiﬁcance a Z 0.10). The relationship
between PEDF expression and clinicopathological variables
was examined by using both a three-level grouping (negative,
1.5, or 1.6) and raw PEDF immunoreactivity scoresTable 1 PEDF Expression among Melanoma Diagnostic Groups
Diagnostic group Sample size
PEDF immuno
Negative
Common melanocytic nevus n Z 13 0 (0)
Dysplastic melanocytic nevus n Z 3 0 (0)
Melanoma in situ n Z 13 2 (15)
Primary cutaneous melanoma n Z 61 16 (26)
Metastatic melanoma n Z 12 6 (50)
Total 102 24 (100)
Percentages have been rounded to add up to 100.
254(0 to 3). These variables included age, sex, anatomic location,
histological subtype, tumor thickness, ulceration, mitotic
index (/mm2), Clark’s level, regression, AJCC stage (I, II, III,
IV), nodal metastases (sentinel and nonsentinel lymph nodes),
organ metastasis, distant metastasis (to skin and soft tissue),
death of disease, and angiogenic parameters, as well as MITF
immunoreactivity. We used Kendall’s tB correlation coefﬁ-
cient to evaluate the association between PEDF expression and
ordinal variables and used ManteleHaenszel c2 test for non-
ordinal variables (sex, anatomic location, and histological
subtype). The unpaired Student’s t-test was used to determine
statistical signiﬁcance (P value) of the association between
mean tumor thickness and PEDF expression. The correlation
between PEDF andMITF immunoreactivity was measured by
both Kendall’s tB and the CORREL function of Microsoft
Excel 2011 with two-tailed Student’s t-test.
Cell Culture and Media
Human melanoma cell lines were obtained from the National
Cancer Institute (NIHeNCI, Rockville,MD) orwere purchased
from ATCC (Manassas, VA). The ARPE19 human RPE cell
line (ATCC) and UACC62 cell line (NCI) were cultured in
Ham’s F10 with 10% fetal bovine serum. Human foreskin pri-
mary melanocytes were purchased from LonzaeClonetics
(Walkersville, MD) andmaintained in TICVAmedium (Ham’s
F10 with penicillinestreptomycineglutamine, 7.5% fetal
bovine serum, 50 ng/mL tetradecanoyl phorbol acetate, 225
mol/L 3-isobutyl-1-methylxanthine, 1 mol/L Na3VO4, and 1
mmol/L dibutyryl cAMP) as described previously.34 For
expression microarray analysis, melanocytes were harbored
from different individuals, purchased fromATCC, and cultured
as above.
Adenovirus Infection and RNA Preparation
Adenoviruses encoding wild-type (WT) MITF, dominant-
negative (DN) mutant MITF, or vector control encoding a
random polypeptide were generated as described previ-
ously.34 In brief, 106 cells were plated per 100-mm plate. On
the second day, cells were overlaid with 2 mL serum-free
Ham’s F10 medium containing 10 mmol/L MgCl2, and
concentrated adenovirus was added at multiplicity of
infection MOIZ 100. The cells were incubated at 37C forreactivity, no. (%)
Low, >0 and 1.5 High, 1.6 Means  SD
9 (69) 4 (31) 1.63  0.63
3 (100) 0 (0) 0.5  0
2 (15) 9 (70) 2.19  1.82
36 (59) 9 (15) 0.93  0.87
6 (50) 0 (0) 0.33  0.44
56 (100) 22 (100)
ajp.amjpathol.org - The American Journal of Pathology
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complete medium was added. Total RNA was isolated with
an RNAqueous-4PCR kit (Ambion; Life Technologies,
Carlsbad, CA) at 48 or 72 hours after infection.
siRNA Gene Silencing
Synthetic siRNAs against MITF and nontargeting control
oligo (siGENOME) were obtained from Thermo Fisher
Scientiﬁc. Cells were transfected with siRNA using lipidoid
reagent C12-113 as described previously35 and were
assayed at 72 hours after siRNA transfection.
Microarray and Gene Correlation Analyses
Expression proﬁling data on human primary melanocytes and
primary melanoma specimens were collected using high-
density oligonucleotide microarrays (Hu6800eHu35KsubA
or HG-U95A; Affymetrix, Santa Clara, CA) as described
previously.32 For correlation studies, the expression level of
MITF or PEDF in each melanoma specimen was shown as
the individual variance from the mean for all melanoma
specimens in the data set (nZ 10).
ChIP Assay
Chromatin immunoprecipitation (ChIP) assays were per-
formed as described previously.32 In brief, 2  106 primary
human melanocytes were grown to logarithmic phase, har-
vested by scraping, and homogenized in a hypotonic buffer
[10 mmol/L Tris-HCl (pH 7.4), 15 mmol/L NaCl, 60 mmol/L
KCl, 1 mmol/L EDTA, 0.1% Nonidet P40, 5% sucrose, 1
complete proteinase inhibitor cocktail (Roche Diagnostics,
Indianapolis, IN)] on ice using a Dounce homogenizer.
Nuclei were isolated by centrifugation onto a 10% sucrose
pad and then were cross-linked with 1% formaldehyde in
phosphate-buffered saline for 20 minutes at room tempera-
ture with gentle shaking. Nuclei were then spun down and
resuspended in ChIP buffer [10 mmol/L Tris-HCl (pH 7.4),
100 mmol/L NaCl, 60 mmol/L KCl, 0.1% Nonidet P40, 1
complete proteinase inhibitor cocktail (Roche Diagnostics)],
then sonicated by two 1-minute pulses on ice using a dis-
membranator (Thermo Fisher Scientiﬁc) ﬁtted with a
microtip. Antibodies [rabbit anti-MITF, rabbit antie
glutathione S-transferase, rabbit antieacetylated histone H4
(all from EMDMillipore)] were then added to a 10-fold ChIP
buffer diluted sample and incubated on a nutator for 3 hours
at room temperature. Ultralink protein-A/G-beads (Pierce;
Thermo Fisher Scientiﬁc) were added to the sample (and to
control samples), which was incubated for an additional hour.
Immunoprecipitates were then washed twice with ChIP
buffer, twice with 500 mmol/L NaCl ChIP buffer, and once
with TriseEDTA (pH 8). The immunoprecipitates were
released from the beads by incubation at 65C for 20 minutes
in 1% SDSeTriseEDTA and protein was digested by pro-
teinase K treatment side by side with an additionalThe American Journal of Pathology - ajp.amjpathol.orgunprecipitated sample as input control. Crosslinks were
released by heating at 70C for 10 hours, and DNAs were
recovered by extraction with phenol and chloroform at high
salt concentration [0.6 mol/L NaOAc (pH 8)] and then were
ethanol-precipitated. Next, semiquantitative PCR was per-
formed on samples to amplify a fragment containing E-boxes
E1/E2/E3 (approximately 250 bp) or the E-box E4 (approx-
imately 300 bp), as well as an upstream control region in the
human SERPINF1 (alias PEDF) genomic locus (2.7 kb
upstream of the transcription start site). The forward and
reverse primers for the E1/E2/E3 region were 50-CTCAAT-
CCCCTCCGGAGAGCCAGG-30 and 50-GCCCACATCA-
AGAAACACAGAAGC-30, respectively. The forward and
reverse primers for the E4 region were 50-TGGCTC-
ACGCCTGTAGTCCCAGCA-30 and 50-AGTACAGAGG-
TACCATCTCGGCTC-30, respectively.
qPCR
The human primers used for quantitative real-time PCR
(qPCR) were as follows. PEDF primers were 50-ATTCCC-
GATGAGATCAGCATTC-30, 50-AACTTTGTTACCCAC-
TGCCCC-30; probe was 50-6-FAM ATCGGAGAGG-
GCACGTACGGAGTTGT-TAMRA-30 (IDT). b-Actin
primers were 50-ATTGCCGACAGGATGCAGAA-30 and 50-
GCTGATCCACATCTGCTGGAA-30; probe was 50-6-FAM-
CAAGATCATTGCTCCTCCTGAGCGCA-30 (IDT). Addi-
tional primers were used as follows: SERPINF1 (PEDF),
forward: 50-AAAAAGCTCTGTGCTGGCTG-30; reverse: 50-
TCCAATGCAGAGGAGTAGCAC-30. MITF, forward: 50-
CATTGTTATGCTGGAAATGCTAGAA-30; reverse: 50-
GGCTTGCTGTATGTGGTACTTGG-30. RPL11, forward:
50-GTTGGGGAGAGTGGAGACAG-30, reverse: 50-TGCC-
AAAGGATCTGACAGTG-30. Reverse transcription pro-
ceeded at 48C, 30minutes; then 40 cycles of PCR at 95C, 15
seconds and at 60C for 1 minute. The total volume of each
reaction was 25 mL. PCRwas performed using anABI PRISM
7700 sequence detection system (Life Technologies) and the
results were analyzed using the manufacturer’s integrated
Sequence Detection System software version 1.7. Standard
curves were generated for all primer sets to conﬁrm linearity of
signals over the experimentally measured ranges. All reaction
assays were performed in triplicate, using b-actin as an
endogenous control. The qPCR was repeated, with the same
results. CT values for each mRNA were normalized to b-actin
(DCT) and calculated as relative quantiﬁcation, RQZ 2
DCt.
Results
PEDF Expression Is Down-Regulated during Melanoma
Progression
Using a monoclonal anti-human PEDF antibody and immu-
nohistochemistry, we examined the expression of PEDF in
102 formalin-ﬁxed, parafﬁn-embedded, well-characterized
melanocytic lesions (n Z 102): 13 CN, 3 dysplastic255
Dadras et almelanocytic nevi, 13 MIS, 61 PCM, and 12 MM (to skin or
lymph node), as well as normal skin (nZ 5). Before scoring
immunoreactivity in the lesions, we examined and estab-
lished the expression pattern for PEDF in normal skin. Weak
to moderate signal was detected in epidermal and follicular
keratinocytes, capillary-size blood vessels in the venus
plexuses, eccrine apparatus, and the intimal layer of large
caliber blood vessels (data not shown). These ﬁnding were
consistent with the low but predictable expression of PEDF in
normal skin and thus served as a positive control for the
study. We established a semiquantitative immunoreactivity
score categorized into a three-level grouping as negative, low
(>0 and 1.5), or high (1.6) (Table 1).
All CN specimens exhibited diffusely positive homoge-
neous immunoreactivity (9/13 low and 4/13 high) in the
cytoplasm and nucleolus of junctional and intradermal
nevus cells (Figure 1, AeC, GeI, and MeO). We compared
PEDF and MITF immunoreactivities in serial sections of the
same CN specimens and found that PEDF was coexpressed
in the MITFþ nevus cells (Figure 1, DeF, JeL, and PeR).
All three specimens of dysplastic melanocytic nevi exhibi-
ted consistently low PEDF expression (Table 1). Most of the
13 MIS specimens (9/13 with high and 2/13 with low
immunoreactivity) retained expression of PEDF; however,
in the remaining two specimens (15%) no PEDF was
detected. By contrast, a majority (52/61) of PCM specimens
(16/61 negative and 36/61 low) exhibited lost to low levels
of PEDF immunoreactivity (Table 1). PCM lesions consis-
tently exhibited strong and diffuse expression of PEDF in
the junctional (in situ) cells, but exhibited decreased to lost
expression in the invasive (dermal component) cells
(Figure 2, AeC and GeI). Interestingly, 9/61 (15%) PCM
specimens exhibited high PEDF immunoreactivity
(Figure 2, MeO and Table 1). MITF was consistently
expressed in the serial sections of PCM specimens, even in
PEDF melanoma cells (Figure 2, DeF, JeL, and PeR).
Overall, we detected signiﬁcantly less PEDF expression in
melanoma cells in vertical growth phase, whereas epidermal
keratinocytes and MIS cells (junctional component) retained
PEDF expression (Figure 2, AeC and GeI).
PEDF was dramatically lost in MM specimens (Figure 3,
AeC and GeI), in which expression of MITF was consis-
tently retained in serial sections (Figure 3, DeF and JeL).
The high endothelial venules (specialized blood vessels in
lymph nodes) stained positive for PEDF, which served as
internal positive control for metastatic lesions to lymph node
(data not shown). Boxplots and KruskaleWallis testing both
conﬁrmed signiﬁcant reduction of PEDF expression in pri-
mary invasive melanoma (PCM) and MM, compared with
CN and MIS (P < 0.0001) (Figure 3M). These results were
independently conﬁrmed by Bonferroni procedure
(Figure 3N). Interestingly, a single MM specimen exhibited
strong PEDF staining, whereas all others were negative; this
specimen was the only one that was separately found to
contain strong ampliﬁcation of MITF (>100 copies using
quantitative genomic PCR).45256Comparison of mean tumor thickness (mm) in PEDFþ and
PEDF melanomas revealed a signiﬁcant inverse correlation
(P Z 0.003) (Figure 3O). The mean thickness for PEDF
melanomas was 3.5 mm and for PEDFþ melanomas was 2.0
mm (Table 2), a ﬁnding consistent with the low to lost PEDF
expression observed in vertical growth phase melanomas.
Our results from examination of 102 melanocytic tumors
spanning several stages of melanoma development demon-
strated a consistent down-regulation of PEDF expression
during tumor progression. Comparison of immunoreactivity
of MITF and PEDF in serial sections of 51 specimens (11
CN, 11 MIS, 7 MM, and 22 PCM) revealed a signiﬁcantly
positive correlation (tB Z 0.35, P Z 0.0003) (Table 3).
Detailed clinicopathological data with clinical follow-up
were available for 41 patients (Table 4). We examined the
relationship between PEDF expression and clinicopatho-
logical characteristics by both a three-level grouping
[negative, low (>0 and 1.5), or high (1.6)] and raw
PEDF immunoreactivity scores (0 to 3). Both methods
yielded nearly identical results, and we report only the three-
level grouping results (Table 4). Higher PEDF expression
was signiﬁcantly associated with distant metastases to skin
and soft tissue (P Z 0.0331). The correlations between
PEDF expression and mitotic index, AJCC stage, nodal
metastases, and blood vascular density were marginally
signiﬁcant (0.05 < P < 0.10).
The PEDF Gene Is a MITF Transcriptional Target in Vitro
Given the observed coexpression of PEDF and MITF in
benign and malignant melanocytic tumors, we investigated
the mechanism of transcriptional control of PEDF expres-
sion by MITF in vitro. Previous experiments using a
microarray-based strategy identiﬁed the PEDF gene as a
potential MITF target in human primary melanocytes.34
Alignment of the human and mouse PEDF genomic loci,
including 5 kb upstream and downstream of the transcrip-
tion start site and the ﬁrst exon, revealed relatively little
sequence conservation, with overall homology of <10%.
Only two stretches of conserved sequence were found, one
located within approximately 380 bp surrounding the tran-
scription start site and the ﬁrst exon (75% identical) and
another region of approximately 400 bp located approxi-
mately 1 kb into the ﬁrst intron (68% identical) (Figure 4A).
The human and mouse PEDF gene promoter regions up to
1.5 kb upstream of transcription start site shared little
sequence homology (18%), suggesting that these regions
might not be important in regulating PEDF gene expression.
The E-box E4 was located 1.3 kb upstream of the tran-
scription start site in the human PEDF promoter and 176 bp
upstream in the mouse PEDF promoter (Figure 4A). The
locations and sequences of these two E-boxes were not
conserved across species. In addition, luciferase reporter
constructs containing either of these two E-boxes failed to
respond to MITF in transient transfection assays (data not
shown), suggesting that these E-boxes were not MITFajp.amjpathol.org - The American Journal of Pathology
Figure 1 Pigment epithelium-derived factor (PEDF) is strongly expressed in the nevus cells of common melanocytic nevi (CN). AeC, GeI, and MeO: Three
representative specimens of CN exhibit diffuse expression of PEDF in both junctional and intradermal nevus cells. PEDF expression is localized to the cytoplasm
and nucleoli (C, I, and O). DeF, JeL, and PeR: Serial sections from the same three specimens show diffuse nuclear and cytoplasmic expression of
microphthalmia-associated transcription factor (MITF). Scale bars: 50 mm (left column); 25 mm (middle column); 6 mm (right column).
PEDF Down-Regulation in Melanomaregulatory elements in vivo. However, examination of the
conserved intronic sequences between the human and
mouse PEDF genes revealed the presence of three E-boxes,
the closest of which was approximately 1.3 kb from theThe American Journal of Pathology - ajp.amjpathol.orgtranscriptional start sites (Figure 4A). Importantly, the ﬁrst
two E-boxes (E1 and E2) were highly conserved between
human and mouse; E-box E3, although very close to E1 and
E2, was not conserved.257
Figure 2 PEDF is signiﬁcantly decreased or lost in invasive melanoma cells. AeC and GeI: Two invasive primary cutaneous melanomas (PCMs), repre-
sentative of a majority [52/61 (85%)] of specimens, exhibited strong expression of PEDF in the junctional (in situ) cells, but expression was decreased to lost
in the invasive cells. MeO: A third PCM specimen is representative of the minority [9/16 (15%)] that retained high levels of PEDF expression. DeF, JeL, and
PeR: Serial sections from the same three specimens show diffuse nuclear and cytoplasmic expression of MITF. Scale bars: 50 mm (left column); 25 mm (middle
column); 12.5 mm (right column).
Dadras et alWe investigated the signiﬁcance of these conserved
E-boxes and their occupancy by MITF in vivo through a ChIP
assay. ProteineDNA complexes in primary human melano-
cytes were cross-linked by formaldehyde, sonicated, and258immunoprecipitated with antibodies against control (gluta-
thione S-transferase), MITF, or acetylated histone H4
(Figure 4B). PCR primers were designed to span E-boxes E1
and E2 (and including E3, because it was physically too closeajp.amjpathol.org - The American Journal of Pathology
Figure 3 Pigment epithelium-derived factor (PEDF) is signiﬁcantly decreased or lost from metastatic melanoma (MM) cells. AeC and GeI: Two repre-
sentative specimens of metastasis to lymph node (AeC) and to subcutaneous adipose tissue (GeI) exhibit a dramatic loss of PEDF expression. DeF and JeL:
Serial sections from the same two specimens show diffuse nuclear and cytoplasmic expression of MITF. M: PEDF immunoreactivity indicates a signiﬁcant loss of
expression in PCMs and MM, compared with CN and melanoma in situ (MIS) by KruskaleWallis test (P < 0.0001). Immunoreactivity data are expressed as
boxplots; the box includes the ﬁrst through third quartiles, a plus sign indicates the median, whiskers indicate the minimum and maximum (excluding
outliers), and black dots indicate outliers. N: Based on multiple pairwise comparisons, Bonferroni procedure conﬁrmed the boxplot analysis and showed a
signiﬁcant difference in PEDF with same color. Within a color, the diagnostic group with the higher level of PEDF is marked with an asterisk. O: In PCM
specimens, tumor thickness was inversely correlated with PEDF expression (P Z 0.003). Data are presented as means  SD. *P < 0.05, **P < 0.01, and
****P < 0.0001. Scale bars: 50 mm (left column); 25 mm (middle column); 12.5 mm (right column).
PEDF Down-Regulation in Melanoma
The American Journal of Pathology - ajp.amjpathol.org 259
Table 2 Inverse Correlation between Tumor Thickness and PEDF
Immunoreactivity According to Positive and Negative Expression in
Primary Cutaneous Melanoma (n Z 40)
Expression
No. of
specimens
Mean
thickness, mm P value
PEDF 11 3.5 0.003
PEDFþ 29 2.0
Table 3 Positive Correlation between PEDF and MITF Immuno-
reactivities According to Positive and Negative Expression in
Melanocytic Lesions (n Z 51)
Diagnostic group
Sample
size
PEDF, no. (%) MITF, no. (%)
þ  þ 
Common melanocytic
nevus
11 11 (100) 0 (0) 11 (100) 0 (0)
Melanoma in situ 11 11 (100) 0 (0) 11 (100) 0 (0)
Primary cutaneous
melanoma
22 11 (50) 11 (50) 20 (91) 2 (9)
Metastatic melanoma 7 1 (14) 6 (86) 6 (86) 1 (14)
Kendall’s tB Z 0.35; P Z 0.0003.
Dadras et alto be reliably discriminated), E4, and a negative upstream
control region 2.7 kb from the transcription start site. This
assay revealed thatMITF is bound to the intronic conserved E-
boxes, as shown by the ampliﬁcation of the E1/E2/E3 DNA
fragment (Figure 4B). Neither PCR ampliﬁcation product was
seen from control or antieglutathione S-transferase antibodies,
nor any ampliﬁcation of either upstream nonconserved E-box
E4 or upstream control region primers. To identify other po-
tential conserved transcription factor binding sites in the
intronic region of the PEDF gene, we conducted an extensive
search of the TRANSFAC database (2006.1 release) using
MatInspector (release 7.4; Genomatix Software, Munich,
Germany) and TESS software (version 2006; http://membres-
timc.imag.fr/Olivier.Francois/tess.html).36 This analysis re-
vealed a conserved HNF4/YY1 binding site in the conserved
intronic sequence (Figure 4A), as well as several potential
binding sites for nuclear receptor superfamilymembers (data not
shown). Importantly, similar analysis of the conserved promoter
region of the PEDF gene spanning the ﬁrst exon revealed only a
conserved CCAAT box and possible binding sites for c-ETS
and the myeloid zinc ﬁnger protein-1, again suggesting that this
region of the PEDF gene is unlikely to be directly regulated
in vivo by MITF. Overall, these results showed that MITF oc-
cupies the endogenous conserved intronicE-boxes in the human
PEDF gene in primary human melanocytes.
To further characterize the relationship between MITF
and PEDF, using anti-PEDF and anti-MITF antibodies,
immunoﬂuorescence localized the PEDF signal to cyto-
plasm and nucleus, whereas the MITF signal was localized
only to the nucleus of human primary melanocytes (data not
shown). qPCR analyses conﬁrmed high levels of PEDF
mRNA in human primary melanocytes, which were on
average decreased 10-fold in all of the melanoma cell lines
examined (Figure 4C). As an independent means for vali-
dation of the MITFePEDF transcription factoretarget
relationship, we examined the correlation of their micro-
array expression proﬁles in a series of primary melanomas.
MITF expression correlated with PEDF gene expression in
the majority of primary melanomas, which independently
corroborated our IHC results (Table 3).
MITF Regulates the Expression of PEDF in Melanocytes
and Melanomas
We next investigated whether PEDF expression can be
regulated by MITF by using an early-passage RPE cell line
(ARPE19), human primary melanocytes, and melanoma cell
lines (UACC62 and SK-MEL-5) and by using two different260gene silencing approaches: DN and siRNA (Figure 5).
MITF up-regulation was achieved by overexpression of WT
MITF (Figure 5, AeD). MITF down-regulation was ach-
ieved in two ways: expression of a DN mutant of MITF
(Figure 5, AeD) or use of two independent siRNAs against
MITF (Figure 5, E and F). We graphed relative mRNA
levels of MITF (suppressed by both siRNAs in both cell
types) and of PEDF (also suppressed by both siRNAs
against MITF in both of these cells (Figure 5, E and F).
ARPE19 cells, primary melanocytes, and UACC62 cells
were infected with adenovirus expressing a random poly-
peptide (control), WT MITF, or DN MITF. We then
measured the endogenous PEDF mRNA and protein fold
changes by qPCR and Western blotting. Compared with
control, WT MITF signiﬁcantly increased (37-fold),
whereas DN MITF reduced (twofold) the endogenous levels
of PEDF mRNA in the RPE cell line ARPE19 (Figure 5A).
In human melanocytes, WT MITF increased the endoge-
nous levels of PEDF mRNA 4.8-fold, whereas DN MITF
reduced levels 2.6-fold, compared with control (Figure 5B).
PEDF protein levels mirrored the changes in PEDF mRNA
levels in primary melanocytes (Figure 5C). Similar changes
were observed in the melanoma cell line UACC62 for PEDF
mRNA (Figure 5D) and protein levels (data not shown).
Using another approach, we found that siMITF markedly
suppressed PEDF mRNA levels in primary melanocytes
(Figure 5E) and in the SK-MEL-5 melanoma cell line
(Figure 5F). Two other melanoma cell lines (MALME-3M
and UACC257) did not respond to siMITF, because of
unusually low endogenous PEDF mRNA levels, despite
relatively high MITF expression (data not shown). These
results suggested that MITF regulates expression of the
endogenous PEDF gene in both melanocytes and mela-
nomas. Taken together with results of the ChIP assay, these
data are consistent with MITF being a direct transcriptional
regulator of the PEDF gene in the cell lines examined.
Discussion
Although the transcription factoretarget gene relationship
between MITF and PEDF has been established in RPE cells,
no previous study has investigated this relationship inajp.amjpathol.org - The American Journal of Pathology
Table 4 Correlations between PEDF Expression and Clinico-
pathological Characteristics of Melanoma Patients (n Z 41)
Characteristic Value
P value,
H:0
t Z 0
Kendall’s
tB*
Age (years) 0.6546 0.05642
Mean 54
Median 54
Range 21e84
Sex 0.34y
Male 26
Female 15
Anatomic location (no.) 0.1471y
Head & neck 7
Upper extremities 9
Trunk 17
Lower extremities 8
Histological
subtype (no.)
0.8008y
Superﬁcial spreading 33
Nodular 6
Lentigo maligna 1
Other 1
Tumor thickness (mm) 0.1413 0.18608
Mean 2.67
Median 1.41
Ulceration (no.) 0.1252 0.23179
Present 9
Absent 32
Mitotic index (/mm2) 0.053 0.25852
Mean 4.9
Median 3
Clark’s level 0.6077 0.07342
II 3
III 11
IV 23
V 4
Regression 40 0.7638 0.04597
Present 7
Absent 33
Clinical follow-up
(months)
0.1076 0.20138
Mean 47.6
Median 34.5
Range 3.9e120.7
AJCC stage 0.0796 0.24762
I 7
II 12
III 3
IV 19
Nodal metastasis 0.0868 0.25889
Positive 21
Negative 20
Organ metastasis 0.3225 0.14956
Positive 12
Negative 29
Distant metastasis 0.0331 0.32215
Positive 19
Negative 22
(table continues)
Table 4 (continued )
Characteristic Value
P value,
H:0
t Z 0
Kendall’s
tB*
Death of disease 0.1273 0.23055
Positive 14
Negative 27
Angiogenic parameters 32
Blood vascular
density (/mm2)
0.0675 0.25894
Mean 52.6
Median 47
Blood vessel size (mm2) 0.3653 0.12821
Mean 662.7
Median 634.82
Blood vascular area (%) 0.3031 0.14596
Mean 3.3
Median 3.2
P values in bold are statistically signiﬁcant (<0.05).
*Positive values of tB denote a positive correlation; negative values, an
inverse correlation.
yManteleHaenszel c2 test.
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We not only examined the expression of PEDF in 102 mela-
nocytic tumors spanning several stages of melanoma devel-
opment (including benign and dysplastic melanocytic nevi,
early-stage radial growth phase to vertical growth phase to
metastatic melanomas), but we also investigated the correlation
of PEDF expression with melanoma clinicopathological prog-
nostic and tumor angiogenic parameters, as well as the mech-
anism of transcriptional regulation byMITF inmelanocytes and
melanoma cells. Expression of PEDF protein, as determined by
semiquantitative IHC, consistently decreased in PCM and MM
specimens, compared with CN and MIS. Moreover, compari-
son of PEDF mRNA and protein level in cultured primary
human melanocytes and established melanoma cell lines
revealed that PEDF was indeed expressed at much higher level
in primary melanocytes than melanomas, supporting the IHC
results. MITF positively correlated with PEDF protein expres-
sion; serial sections clearly showed thatMITFþmelanoma cells
indeed expressed PEDF. Comparison of MITF and PEDF
mRNA levels by microarray expression values conﬁrmed the
positive correlation between MITF and PEDF expression in
primary melanomas. These data are consistent with a model in
which PEDF expression is down-regulated in the majority
of noneMITF-ampliﬁed melanomas but is retained in the
minority (15%) of MITF-ampliﬁed lesions examined here.
MITF is a melanocyte-speciﬁc transcription factor whose
targets are essential for melanocyte differentiation, as well as
for survival.29 We have now identiﬁed the gene for PEDF
(which is an antiangiogenic factor in retinal homeostasis37) as
another MITF target gene in melanocytes and melanoma cells.
Comparison of retinal epithelium and cutaneous epidermis
may help explain this novel role of MITF as a regulator
of PEDF expression in human skin. The epidermis is an261
Figure 4 Identiﬁcation of the PEDF gene as a target MITF in human pri-
mary melanocytes. A: Alignment of human and mouse PEDF genomic loci
revealed conserved MITF binding sites (E-boxes) in the ﬁrst intron. Dashed
lines bracket two highly conserved regions of the PEDF genome. Arrowsmark
the transcription start site and the ﬁrst exon; vertical bars represent E-boxes.
E1 and E2 (gray bars), are conserved between human (h) and mouse (m)
sequence; E3 and E4 (black bars) are not conserved between the two species.
The sequence alignment of the conserved intronic region is shown, E-boxes
anda conservedHNF4/YY1 site are labeled.B: In vivooccupancy of the intronic
E-boxes by MITF is shown by PCR ampliﬁcation of immunoprecipitated chro-
matin DNA. Chromatin from human primary melanocytes was sonicated and
precipitated by control, antieglutathione S-transferase (GST), anti-MITF, or
antieacetylated histone (Ac-Histone) antibodies. The input DNA represents
5% of the amount of the total DNA used in the ChIP assay. The primers for the
upstream control region (UCR) were approximately 2.7 kb upstream of the
transcription start site; the E4 and E1/E2/E3 primers span E-boxes in the
human PEDF gene promoter and the ﬁrst intron. C: The qPCR analysis shows
markedly decreased PEDF mRNA levels in melanoma cell lines, compared with
human primary melanocytes. All reaction assays were performed in triplicate,
using b-actin as an endogenous control. CT values for each mRNA were
normalized to b-actin and calculated as relative quantiﬁcation RQZ 2DCt.
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262avascular epithelium, in this way resembling the retina. Only
during injury or wound healing does the skin becomes
extensively vascularized as a physiological response.38 The
concentration of PEDF in the epidermis and cutaneous
vasculature supports the notion that it may contribute to
maintenance of an antiangiogenic state in the skin, possibly
through MITF-driven PEDF expression in melanocytes, along
with either low-level expression within keratinocytes or,
conceivably, through transferring to nearby keratinocytes from
melanocytes via melanosomes.39 Thus, MITF regulation of
PEDF expression in epidermal keratinocytes and melanocytes
may contribute to the maintenance of an antiangiogenic bal-
ance in skin under normal physiological conditions.
Previous studies have implicated the tumor suppressive role
of PEDF in pancreatic and prostate carcinoma40,41 and in
mouse melanoma xenograft models.25,26 If melanoma growth
in a mouse xenograft model were a surrogate for the depth of
invasion in humanmelanoma, then PEDFmelanomas should
be thicker. Indeed, in the present study PEDF levels were
absent to low in themajority [52/61 (85%)] of PCM specimens
(Table 1), and PEDF expression was lost in thicker invasive
melanomas (3.5 mm), compared with thinner lesions (2.0mm)
(Table 2). Moreover, PEDF expression was retained in MIS
specimens and in the in situ component of invasive specimens
but was lost in invasive dermal cells (vertical growth phase),
supporting the notion that loss of PEDF expression enhances
tumor growth. However, a study examining the relationship
between PEDF expression and tumor angiogenesis in 32 pri-
mary invasive melanomas revealed only a marginal signiﬁ-
cance for blood vascular density and no signiﬁcance for blood
vessel size or blood vascular area,8 three important determinants
of angiogenesis in tumor tissue sections. In the present study,
comparison of PEDF expression with ulceration and mitotic
index (two other major AJCC prognostic parameters in mela-
noma) revealed no signiﬁcant correlation. Except for distant
metastases, PEDF expression did not show any signiﬁcant
relationship to other parameters of disease progression
(including death of disease, organ metastasis, nodal metastasis,
or AJCC stage) during an average of 47.6 months of clinical
follow up in 41 melanoma patients. These results indicate that
tumor angiogenesis can inﬂuence melanoma growth (invasive
depth) but not survival outcome, consistent with the notion that
other factors (eg, tumor lymphangiogenesis) are signiﬁcantly
associatedwithmelanoma prognosis, as evidenced by a number
of published studies and a recent meta-analysis.18 Alternatively,
the number of patients in our present analysis may be too small
to detect a statistically signiﬁcant difference.
To further scrutinize the intimate correlation between
MITF and PEDF tissue expression, we investigated the
mechanism of transcriptional control of MITF on PEDF in
melanocytes and melanoma cells. We identiﬁed two
conserved E-boxes in the ﬁrst intron of the human and mouse
PEDF genes using binding assays in vivo and demonstrating
direct inﬂuence of MITF on PEDF by using DN and siRNA
approaches in vivo. The high conservation of both sequence
and positions for these E-boxes, together with the absence ofajp.amjpathol.org - The American Journal of Pathology
Figure 5 MITF regulates PEDF gene expression in vivo, as demonstrated by both DN and siRNA gene silencing methods. A and B: qPCR analysis of PEDF
mRNA levels in RPE cells (ARPE19) (A) and primary melanocytes (B) after infection with adenovirus expressing a random polypeptide control, WT MITF, or DN
MITF shows a marked increase in endogenous PEDF mRNA levels by functional MITF and a decrease by nonfunctional MITF in RPE cells and melanocytes,
compared with control. C: In accord, a marked increase in PEDF protein levels was demonstrated in melanocytes expressing WT MITF, and a marked decrease in
DN MITF melanocytes, compared with control. D: Similarly, marked increase and decrease in PEDF mRNA levels were demonstrated in melanoma cell line
(UACC62) expressing WT and DN MITF, respectively, compared with control. E and F: In two independent experiments, siMITF markedly decreased both MITF
and PEDF mRNA levels in melanocytes (E) and in the melanoma cell line SK-MEL-5 (F). Ctrl, control; DN, dominant negative; WT, wild type.
PEDF Down-Regulation in Melanomaconserved E-boxes in the proximal promoter region, sug-
gests a mechanism of intronic gene regulation through a
MITF-dependent enhancer element. Indeed, the ChIP assay
conﬁrmed the speciﬁc binding of MITF to the conserved
E-boxes, but not to upstream, nonconserved E-box se-
quences. The ability of MITF to modulate PEDF gene
expression through an intronic enhancer is plausible, given the
prior demonstration that MITF regulates the melanocyte-
lineage gene PMEL through a similarly positioned, species-
conserved enhancer element located within the ﬁrst intron.42
Given that the E-boxes were located at an intronic location
(and not within the promoter region), the use of luciferase
reporter assays would have been artiﬁcial, because the intron
would have been removed from its natural location to reside in
a usable plasmid reporter. Instead, the ChIP assay provided
direct evidence for the interaction ofMITFwith the E-boxes of
PEDF. Taken together, these results are consistent with a
MITFePEDF transcription factoretarget relationship.
To validate PEDF as a MITF target, melanocytes and
melanoma cells were enforced to express DN MITF or
siMITF. In both approaches, PEDF endogenous mRNA
(and protein) levels directly increased in response to WT
MITF, but decreased on suppression of MITF (by DN or
siRNA) in melanocytes and melanoma cell lines. Therefore,
given binding of endogenous MITF to a conserved
consensus element within the ﬁrst intron of PEDF, it is
likely that it regulates the PEDF gene directly, not indi-
rectly. PEDF is also expressed within nonmelanocytic cell
types (eg, keratinocytes, prostate, and pancreas) that are not
known to express MITF. It is possible that the closelyThe American Journal of Pathology - ajp.amjpathol.orgrelated MITF family members TFEB, TFE3, or TFEC may
modulate PEDF in these nonmelanocytic cell types (as has
been seen for cathepsin K expression in osteoclasts43) or,
alternatively, distinct transcriptional mechanisms may
regulate PEDF in these cell types. Despite the involvement
of MITF in regulating PEDF expression, it remains
incompletely understood exactly which mechanism or
mechanisms are responsible for PEDF down-regulation
during progression of melanocytic neoplasm. One possi-
bility is that MITF expression is largely responsible,
because its expression tends to diminish,44 although in a
minority of specimens MITF is ampliﬁed.45 Similarly, in the
present study PEDF down-regulation was measured within
intermediate-thickness cutaneous melanomas, and the
diminished expression was seen to correlate with metastatic
propensity. Therefore, down-regulation of MITF should
similarly affect PEDF expression. Although it is possible
that selection for MITF down-regulation could arise from
growth beneﬁts associated with diminished differentiation
and/or pigmentation, it is also possible that loss of PEDF
expression may contribute (and perhaps even more impor-
tantly) to this selection.
Finally, PEDFhas been observed to harbor potent endothelial
killing activity, aswell as antineoplastic activity againstmultiple
solid tumors in animal models.40,41 Moreover, enforced over-
expression of PEDF in melanoma cells can lead to growth in-
hibition and tumor necrosis in xenograftedmousemodels and to
prevention of lung metastases in mice injected with melanoma
cells.26 These reports appear to be highly complemented by our
ﬁndings of a MITFePEDF transcription factoretarget263
Dadras et alrelationship and down-regulation of PEDF expression as a po-
tential angiogenic factor during early melanoma invasive
growth. A thorough understanding of the mechanisms regu-
lating PEDF expression in melanoma may lead to novel thera-
peutic strategies aimed at restoring its expression in advanced
disease.46 A proof of principle using such a strategy has recently
been shown in pancreatic cancer models, in which adenoviral-
mediated PEDF gene transfer inhibited tumor growth and
intraperitoneal metastasis.47 Because suppression of PEDF-
mediated antiangiogenesis may confer advantageous tumor
growth, aiming to reactivate PEDF expression might be a
plausible therapeutic strategy for melanoma.
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